Our study: Total | HoLEP [21] | OP [21] | ThuVEP [20] | |||||
---|---|---|---|---|---|---|---|---|
P-value* | P-value* | P-value* | ||||||
Patients, N | 125 | 60 | 60 | 1382 | ||||
Preoperative IPSS, points | 27.09 ± 5.91 | 22.1 ± 3.3 | < 0.0001 | 21.0 ± 3.6 | < 0.0001 | 18.6 ± 7.6 | < 0.0001 | |
Postoperative IPSS, points | 7.35 ± 5.89 | 2.4 ± 1.9 | < 0.0001 | 2.8 ± 3.9 | < 0.0001 | |||
PVR volume, mL | Preoperatively | 329.76 ± 350.52 | 280 ± 273 | 0.2915 | 292 ± 191 | 0.3438 | 156.3 ± 195.4 | < 0.0001 |
Maximum UFR, mL/s | 9.93 ± 5.02 | 3.8 ± 3.6 | < 0.0001 | 3.6 ± 3.8 | < 0.0001 | 10.7 ± 6.5 | 0.11 | |
Mean UFR, mL/s | 5.40 ± 2.18 | |||||||
PVR volume, mL | 1 week postoperatively | 60.67 ± 74.08 | 10.2 ± 22.4 | < 0.0001 | ||||
Maximum UFR, mL/s | 19.39 ± 12.01 | 24.7 ± 3.3 | < 0.0001 | |||||
Mean UFR, mL/s | 11.24 ± 6.38 | |||||||
PVR volume, mL | 1 month postoperatively | 53.97 ± 36.05 | 6.3 ± 18.7 | < 0.0001 | 3.8 ± 8.7 | < 0.0001 | ||
Maximum UFR, mL/s | 17.92 ± 9.3 | 26.9 ± 7.9 | < 0.0001 | 26.6 ± 6.1 | < 0.0001 | |||
Mean UFR, mL/s | 11.09 ± 5.78 | |||||||
PVR volume, mL | 3 months postoperatively | 38.67 ± 18.52 | 7.2 ± 18.8 | < 0.0001 | 3.0 ± 7.7 | < 0.0001 | 32.9 ± 67.2 | 0.0186 |
Maximum UFR, mL/s | 23.20 ± 6.87 | 27.6 ± 7.0 | < 0.0001 | 27.3 ± 6.2 | < 0.0001 | 19.2 ± 10.6 | < 0.0001 | |
Mean UFR, mL/s | 10.20 ± 3.77 | |||||||
PVR volume, mL | 6 months postoperatively | 48.22 ± 45.85 | 4.4 ± 11 | < 0.0001 | 2.1 ± 6.0 | < 0.0001 | ||
Maximum UFR, mL/s | 9.38 ± 13.98 | 29.9 ± 8.8 | < 0.0001 | 27.0 ± 0.5 | < 0.0001 | |||
Mean UFR, mL/s | 18.28 ± 8.96 | |||||||
PVR volume, mL | 12 months postoperatively | 41.33 ± 42.02 | 5.8 ± 16.7 | < 0.0001 | 6.4 ± 12.3 | < 0.0001 | ||
Maximum UFR, mL/s | 19.00 ± 18.30 | 27.4 ± 9.7 | < 0.0001 | 28.3 ± 7.5 | < 0.0001 | |||
Mean UFR, mL/s | 7.50 ± 4.71 | |||||||
Reduction ratio of the estimated prostate size postoperative (%) | 74.17 ± 11.27 | 82 | 85 | 61 |